Research
Hormonal
In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia.
Retatrutide may improve glycemic control in patients with type 2 diabetes.
StrongSupportsmedium confidence
In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia (HbA1c < 5.7%).
Why this rating
Based on Phase 2 clinical data from a controlled study.
Source
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
Ashwin A. Pillai et al. · Cardiology in Review · 2026
DOI 10.1097/crd.0000000000001310
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →